Oragenics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OGEN research report →
Price Chart
About the company
Oragenics, Inc. (OGEN) is a U. S.
- CEO
- Janet Huffman
- IPO
- 2004
- Employees
- 3
- HQ
- Lakewood Ranch, FL, US
Get TickerSpark's AI analysis on OGEN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.20M
- P/E
- -0.14
- Fwd P/E
- 1.68
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.59
- EV/EBITDA
- 0.23
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -144.23%
- ROIC
- -279.54%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-9,362,503
- Net Income
- $-9,842,487+6.9%
- EPS
- $-4.56-185.0%
- OCF Growth
- -107448.9%
- FCF Growth
- -107448.9%
- 52W High
- $1.45
- 52W Low
- $0.46
- 50D MA
- $0.51
- 200D MA
- $0.65
- Beta
- 1.25
- RSI (14)
- 46
- Avg Volume
- 29.43K
No earnings-call transcripts are available for OGEN yet.
- Free Float
- 98.1%
- Shares Outstanding
- 4.51M
- Float Shares
- 4.42M
of shares held by institutions
20 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Geode Capital Management, LLC | 23.68K | ▼ 41.39K |
| 25 LLC | 23.16K | ▲ 23.16K |
| Jane Street Group, LLC | 12.77K | ▲ 12.77K |
| Tower Research Capital LLC (Trc) | 4.55K | 0 |
| St. Johns Investment Management Company, LLC | 1.92K | ▲ 1.72K |
| Blackrock, Inc. | 703 | 0 |
| Ubs Group AG | 642 | ▼ 4.56K |
| Wells Fargo & Company/Mn | 34 | 0 |
| Harbour Investments, Inc. | 34 | 0 |
| Sbi Securities Co., Ltd. | 23 | ▲ 12 |
| Adkins Seale Capital Management LLC | 3 | 0 |
| Bogart Wealth, LLC | 1 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Spencer John | other | 55,900 |
| Jul 1, 26 | Spencer John | other | 0 |
| Jul 1, 26 | Spencer John | other | 10,000 |
| Dec 12, 25 | Telling Fred | sell | 210 |
| Dec 11, 25 | Huffman Janet | other | 250,000 |
| Dec 11, 25 | Giordano Natasha | other | 125,000 |
| Dec 11, 25 | Giordano Natasha | other | 38,320 |
| Dec 11, 25 | Telling Fred | other | 125,000 |
| Dec 12, 25 | Telling Fred | sell | 210 |
| Dec 11, 25 | GANDOLFO JOHN P | other | 125,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OGEN coverage
Recent articles, reports, and earnings notes.
No research on OGEN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OGEN report →Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum
globenewswire.com · Sep 16
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
globenewswire.com · Aug 28
Oragenics (NYSEAMERICAN:OGEN) Trading Up 0.2% – Time to Buy?
defenseworld.net · Aug 12
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
globenewswire.com · Jul 7
Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21
globenewswire.com · May 19
ORAGENICS PROVIDES INVESTOR UPDATE
globenewswire.com · May 18
ORAGENICS PROVIDES INVESTOR UPDATE
globenewswire.com · May 18
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
globenewswire.com · May 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.